Oric is a cash-rich, pre-revenue oncology biotech offering asymmetric upside if rinzimetostat’s safety edge and enozertinib’s brain-penetrant profile translate into pivotal clinical success.
Overview
Oric Pharmaceuticals is a pre-revenue clinical-stage oncology company developing small-molecule therapies designed to overcome cancer resistance. Its investment case centers on rinzimetostat for metastatic castration-resistant prostate cancer and enozertinib for EGFR-mutant NSCLC, particularly brain-metastatic disease. Neither drug is approved, so value depends on clinical success, future approvals, partnerships, and eventual commercialization. The company’s differentiation lies in rinzimetostat’s tolerability and enozertinib’s brain penetration, both addressing meaningful unmet needs in large oncology markets.